A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis.
Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC).
Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.